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Introduction
 Despite the decline in the global incidence, gastric 
cancer (GC) remains the second leading cause of cancer 
death and fourth most common malignancy worldwide 
(Jemal et al., 2011). The GC prevalence is associated 
with environmental triggers, host genetic, and bacterial 
factors. In the last case, Helicobacter pylori infection is a 
major contributor to the development of this malignancy 
(Malakar et al., 2012; Zabaleta, 2012). Despite the 
common use of multimodal therapy [chemotherapy, 
radiation and surgery], there is a few long-term disease-
free survival rate for GC patients, therefore, further 
significant studies are required in this field.
 Before the 80s, RNA was only considered as an 
intermediate for the passive information transport between 
DNA and protein synthesis. With the discovery of catalytic 
properties of RNA in the early 80s, a Nobel Prize was 
shared between Tom Cech and Sidney Altman (Waldrop, 
1989). Since then, several researchers are continuously 
striving for new strategies and future challenges.
 Over the past decades, several tumor suppressor genes 
and proto-oncogenes have their role established in the 
development and progression of GC, thereby making 
these insights, a potentially attractive therapeutic target 
in this disease. Among these findings, an innovative 
and evolutionary mechanism called RNA interference 
(RNAi) is revolutionizing oncology (Wang et al., 2011). 
RNAi was discovered by Fire et al. (1998), and it was 
defined as a posttranscriptional gene-silencing mechanism 
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Abstract
 Gastric cancer (GC) remains a virtually incurable disease when metastatic and requires early screening tools 
for detection of early tumor stages. Therefore, finding effective strategies for prevention or recurrence of GC 
has become a major overall initiative. RNA-interference (RNAi) is an innovative technique that can significantly 
regulate the expression of oncogenes involved in gastric carcinogenesis, thus constituting a promising epigenetic 
approach to GC therapy. This review presents recent advances concerning the promising biomolecular mechanism 
of RNAi for GC treatment. 
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produced by small double-stranded RNAs which include 
endogenous microRNA (miRNA) and exogenous small 
interfering RNA (siRNA) or short hairpin RNA (shRNA). 
These are all commonly cleavage by endogenous enzyme 
called Dicer that gives rise to the important transcription 
factors involved in the gene expression regulation. This 
methodology’s greatest potential is to specifically repress 
the transcription of disease-causing genes thus avoiding 
undesirable effects. This is possible due to the fact that 
RNAi acts exclusively on the endogenous mechanism 
called RNA induced silecing complex (RISC) which 
acts as an endonuclease on target messenger RNA 
(mRNA). Thus, the gene expression is controlled at the 
post-transcriptional level through the recognition and 
cleavage of mRNA in association with RISC (Baulcombe, 
2000; Matzke et al., 2001; Bader et al., 2010; Wilson and 
Plucinski, 2011). Figure 1 shows a simplified scheme of 
the functioning mechanism of RNAi.  
 It is estimated that there are about 900 human miRNA’s 
not yet characterized with respect to their biological 
targets and cellular functionality. Among these, a number 
of miRNA are involved in carcinogenesis and other 
pathological conditions (Bader et al., 2010). shRNA is 
a double-stranded RNA by flipping back on the loop 
sequence, hence the term “short hairpin”, and it can be 
used to silence target genes expression by RNAi technique. 
In this case viral vectors or plasmids are used (Rao et al., 
2009). 
 RNAi has great genetic and epigenetic importance 
as it acts as a key component in cellular differentiation 
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and progression processes in normal and tumor tissues 
(Fire et al., 1998), thus, several investigators have 
focused their attention to the possible antitumor activity 
of this new epigenetic mechanism in GC. The term 
“epigenetics” involves an inherited phenotype resulting 
from chromosomal alterations without changes in the DNA 
sequence. Briefly, epigenetic events in humans provide a 
more stable and precise control of gene expression over 
multiple generations (Berger et al 2009). These epigenetic 
events are important in all aspects of biology and research. 
In the last decade, they have been directly related to 
carcinogenesis and tumor progression. Currently, four 
different epigenetic systems are recognized. They are, 
in brief: Self-sustaining metabolic cycle (Ferrel, 2002; 
Thieffry and Sanchez, 2002), Chromatin-marking systems 
(Weissmann and Lyko, 2003), Structural inheritance 
(Collinge, 2001), and RNAi system (Hannon, 2002). All 
these epigenetic events are involved in the gene expression 
regulation, either by gene activation or silencing.
 Thanks to recent technological advances, the RNAi 
is chemically synthesized and soon become an effective 
therapeutic tool against several diseases as it shows a 
huge therapeutic benefit in these experimental trials. 
From a practical perspective, the RNAi approaches 
are becoming promising as an attractive therapeutic 
alternative for GC patients, due to its ability to selectively 
inhibit the expression of oncogenes involved in human 
gastric carcinogenesis. Thus, it becomes necessary to 
better understand this revolutionary approach in several 
experimental models of treatments targeting future clinical 
applications. This review aims to bring together the 
latest advances concerning the promising biomolecular 
mechanism of RNAi for GC treatment, and besides, 
to report the future perspectives that might contribute 
to the further understanding and treating this disease. 
Additionally, to clarify a number of concepts and methods 
related to this innovative therapy.
Promising Therapeutic Targets for Treatment 
of Gastric Cancer by RNAi Silencing.
 Epidemiologists and public health researchers from 
several institutions reported a global decline in GC 
mortality (Crew and Neugut, 2006; Jemal et al., 2011). 
However, the advances in new therapies and approaches, 
the GC treatment have been shown to have a limited 
impact on the overall survival of these patients. 
 The promising epigenetic therapy using RNAi is in 
development and several oncogenic targets involved in 
drug resistance, anti-apoptosis specific, angiogenesis and 
survival are being studied. Recently discovered promising 
therapeutic targets for GC treatment by RNAi silencing 
are listed below. 
 The homeobox protein Nanog is an important 
transcription factor in the pluripotency of embryonic 
stem cell and the preservation of self-renewal (Pan and 
Thomson, 2007). Expression of Nanog has also been 
correlated with the clinical classification of GC and 
invasion of GC cells, additionally, its overexpression 
correlates with poor prognosis patients with CG (Lin et 
al., 2012). In this way, Ji and Jiang (2013) used shRNA 
to inhibit the expression of the Nanog gene to study the 
effect on the tumor biological behavior of the SGC-7901 
GC cell line. The results revealed that RNAi technology 
was able to inhibit the expression of Nanog, thereby 
inhibiting tumor cell proliferation, migration and invasion. 
This method may provide an experimental basis for a gene 
therapy approach for treating GC.
 The STMN-1 gene, which encodes the Stathmin-1/
oncoprotein, its function as an essential regulatory protein 
of microtubule dynamics has been typified (Sobel, 1991) 
and was found overexpressed in a large number of human 
cancers, such as leukemia (Melhem et al., 1991), prostate 
(Friedrich et al., 1995), breast (Brattsand, 2000), and 
lung cancer (Chen et al., 2003). To establish the silencing 
effects of Stathmin-1, some researchers used the shRNA 
to knockdown, STMN-1 mRNA in MKN-45 GC cell line. 
The results showed that the silencing of stathmin1 has led 
to the significant decrease in proliferation and inhibition 
of cell migration in vitro and in nude mice (Akhtar et 
al., 2013). Stathmin-1 oncoprotein has been shown to 
be a potential oncogene target that which is a promising 
strategy to treat GC.
 Coiled coil domain containing 134 (CCDC134) is 
a promising gene therapeutic method and studies have 
shown that it regulates the Erk1/2 and JNK/SAPK 
pathways in HeLa cells (Huang et al., 2008). From this, 
other investigators wondered if this gene could be play 
a role in GC development or tumor progression, and 
thus used siRNA technology and CG cell lines in this 
investigation. Notably, these reports have demonstrated 
that CCDC134 siRNA knockdown caused a significant 
Figure 1. The three Methods of Gene Silencing by 
RNA Interference (RNAi) Used in the Experimental 
Treatment of Gastric Cancer (GC) by the Researchers. 
In method (1) cells can be directly transfected with short hairpin 
RNA (shRNA) carried by plasmids. In method (2) lentiviral 
particles are used. Both can be employed to transport and 
transcribe shRNA in the cell line of interest. After transcription, 
the expressed shRNA is released from the nucleus and cleaved 
by the Dicer enzyme in the cytoplasm, generating the siRNA. 
In (3) the synthetic siRNA can be directly transfected and 
enters the RNAi pathway. From this point, all siRNA in the 
cytoplasm is recognized by the RISC complex (RNA induced 
silecing complex), which, once activated, mediates cleavage 
and destruction of the target oncogene mRNA, thus silencing 
the protein responsible for GC
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increase in invasion and migration of AGS CG cell lines 
(Zhong et al., 2013). The CCDC134 may be a candidate 
for a therapeutic target of GC.
 The MUC1 mucin core protein is aberrantly expressed 
in malignancies, such as in stomach cancer (Ng et al., 
2008) and recently its overexpression was reported to be 
involved in trastuzumab resistance. In that study, siRNA 
of MUC1 into drug-resistant MKN45 GC cell line was 
used to observe the silencing effects. The authors observed 
that the sensitivity to trastuzumab under MUC1 siRNA 
conditions was significantly increased (Deng et al., 2013). 
Therefore, this resistance can be cancelled by using the 
RNAi approach.
 Some researchers showed that the overexpression 
of Bcl-2 gene can inhibit tumor cell apoptosis induced 
CCDC134 (Bilim et al., 2008). Therefore, Liu and Lu, 
(2013) synthesized siRNA to transfect BGC823 GC cell 
line and observed the influence of inhibiting Bcl-2 gene 
expression on the apoptosis and radiosensitivity. These 
investigators demonstrated that Bcl-2 knockdown can 
effectively inhibit the expression of Bcl-2 gene and thus 
enhance the radiosensitivity and apoptosis of GC BGC823 
cells. These findings indicate that Bcl-2 gene silencing 
may be a promising novel approach for treatment of GC.
 Ras-related protein (Rab-25) is a newly identified 
protein encoded by the RAB25 gene belonging to the Ras 
oncogene family and currently recognized as CATX8, in 
additional, Rab25 was closely related to tumorigenesis and 
metastasis (Chia and Tang, 2009). In a study with GC cell 
lines using siRNA silencing, Cao et al., (2013) showed 
that Rab25 protein expression positively associated with 
the development of GC and that Rab25 is involved in 
the invasion and metastasis of GC cells. Those authors 
hypothesized that knockdown of Rab25 may be a potential 
future biological treatment strategy for inhibition of 
invasion and metastasis of human GC.
 Vascular endothelial growth factor A and C (VEGF-
A/C) were considered as most important factor in 
the angiogenesis, and further, the GC patients that 
overexpression of VEGF were correlated with peritoneal 
dissemination and poor prognosis (Aoyagi et al., 2005). 
Recently, Wang et al. (2013) correlated the VEGF-
A/C expression with clinicopathologic parameters and 
prognosis in patients with GC using the plasmid shRNA 
therapy targeting VEGF-A. These researchers established 
that the expression of VEGF-A/C predict worse prognosis 
of GC patients and the silencing  of VEGF-A/C markedly 
suppresses cancer growth than silencing of VEGF-A or 
VEGF-C (Wang et al., 2013). Their findings provide a 
novel strategy for the treatment of GC using the VEGF-
A/C gene as target.
 AKT1 (akt murine thymoma viral oncogene homolog 
1) enzyme is a serine/threonine kinase encoded by AKT1 
gene. It plays a key role in cell metabolism such as 
growth and survival. Some studies confirm that AKT1 is 
overexpressed in a variety of human cancers including 
GC and may be related to chemoresistance to drugs (Oki 
et al., 2005; Lindsley, 2010). AKT1 expression was then 
silenced in GC cell lines using the shRNA method. This 
silencing increased chemosensitivity to cisplatin in those 
cell lines by in vitro and in vivo apoptosis induction (Zhou 
et al., 2012). The results suggested that the AKT1 gene 
could be considered as a therapeutic target in combination 
with cisplatin in GC patients. 
 The APRIL (A Proliferation-Inducing Ligand) gene 
belongs to the TNF (tumor necrosis factor) family and 
was first identified in cell lines and primary samples from 
various tumor lesions. It is also recognized for its ability 
to stimulate tumor cell proliferation (Hahne et al., 1998). 
As a result, an siRNA specific for APRIL mRNA was 
designed and transfected different GC cell line cultures. 
The researchers successfully demonstrated the inhibition 
of cell viability and colony formation due to cell cycle 
arrest in the G2/M phase (Cui et al., 2012). These findings 
provide new clues to the investigation of GC malignant 
proliferation using the APRIL gene as target. In the 
same way, other authors (Ni et al., 2012) constructed a 
specific shRNA vector aimed at human APRIL gene and 
transfected into GC sgr-7901 cells. The results showed that 
APRIL gene silencing can increase the apoptotic rate of 
GC cells. Their study suggests that APRIL gene silencing 
may be useful in GC treatment. 
 CDX2 (Caudal type homeobox 2) is a gene encoded 
in the villi of intestinal cells. It plays a crucial role in 
the regulation of cell proliferation and differentiation 
in the intestine, besides being involved in resistance to 
chemotherapy (Suh and Traber, 1996; Lorentz et al., 
1997; Silberg et al., 2000) and being overexpressed in 
GC (Mizoshita et al., 2003). In a study with GC cell lines 
using siRNA silencing, it was demonstrated that the CDX2 
gene plays a critical role in the proliferation, invasion and 
apoptosis of GC cells. The researchers thus succeeded in 
reducing both in vitro and in vivo progression (Wang et 
al., 2012). Their study suggests new basis for the treatment 
of GC with gene manipulation by using siRNA.
 Recently, genes that express ion transport proteins 
have been studied in several cancers, including the CLIC1 
(chloride intracellular channel 1) gene, which encodes 
the intracellular chloride channel (Kunzelmann, 2005; 
Schönherr 2005). RNAi technology was used to target 
the CLIC1 gene in GC cell culture. The results showed 
that siRNA can efficiently inhibit CLIC1 expression and 
suppress in vitro GC migration and invasion (Peng-Fei 
et al., 2012). However, this silencing maintained GC cell 
proliferation and reduced apoptosis. 
 The CTGF (Connective Tissue Growth Factor) gene 
expresses connective tissue growth factor and plays 
a major role in many biological processes, besides 
being associated with various cancers development and 
progression (Xie et al., 2001; Yang et al., 2005; Sala-Torra 
et al., 2007). Chinese researchers have investigated the 
role of CTGF gene in GC cell lines and cells obtained 
from tissues of patients undergoing gastrectomy. After 
transfection with an siRNA targeted to the CTGF gene 
mRNA, they demonstrated that gene silencing promoted 
the adhesion of GC cells to the peritoneum, thereby 
hindering spread and metastasis in these in vitro assays 
(Jiang et al., 2012). Thus, the CTGF gene may be a new 
and promising therapeutic target.
 The EPHA2 (ephrin type-A receptor 2) receptor is 
a protein encoded by the EPHA2 gene. It belongs to 
the protein tyrosine kinase family and has been initially 
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related to events in the nervous system (Sulman et al., 
1997). Emerging evidences demonstrate EPHA2 gene 
overexpression in tumor progression, angiogenesis and 
metastasis in many cancers (Duxbury et al., 2004; Ireton 
and Chen, 2005). To further define the EPHA2 gene 
function in malignant invasion, researchers used the 
siRNA technique to inhibit this gene expression in GC cell 
lines. The results showed that silencing EPHA2 receptor 
expression inhibited proliferation by stopping the cell 
cycle and decreased in vitro invasion (Yuan et al., 2012). 
Therefore, this silencing may be a valuable approach to 
GC therapy.
 hMex-3A (human Mex-3A) is an RNA binding 
protein that plays essential roles in its metabolism, such 
as transportation, surveillance and translation. This 
protein is overexpressed in several diseases, including 
cancer (Buchet-Poyau et al., 2007). A recent study has 
demonstrated for the first time that the silencing of 
hMex-3A by siRNA effectively inhibits cell proliferation 
and the migratory ability of GC cell lines. The results 
suggested that this gene functions as a candidate oncogene 
in the development and metastasis of GC (Jiang et al., 
2012). Therefore, the hMex-3A gene may be suitable as 
a potential target for the epigenetic treatment of GC.
 Interleukin-8 (IL-8) is a well-known cytokine in 
gastric carcinogenesis as it attracts neutrophils to sites 
infected with the Helicobacter pylori causing chronic 
gastritis, gastric atrophy, intestinal metaplasia, dysplasia 
and finally GC (Lindley et al., 1988; Matsushima et al., 
1988; Dixon, 1991; Crabtree et al. 1994). Therefore, 
siRNA was specifically synthesized to hybridize and 
destroy IL-8 mRNA in GC cell lines. It was demonstrated 
that in absence of IL-8 there was no tumor cell migration 
or invasion. On the other hand, GC cells have developed 
resistance to oxaliplatin in in vitro chemosensitivity assays 
(Kuai et al., 2012). These findings may contribute to the 
development of new GC treatments with the IL-8 gene as 
a therapeutic target. However, this technique which may 
lead to oxaliplatin chemoresistance.
 KLF8 (Kruppel-like factor 8) is a protein that plays an 
important role in the regulation of epithelial-mesenchymal 
transition, which comprehends homeostatic mechanisms 
that regulate tissue repair, inflammation and wound 
healing. On the other hand, this protein is also expressed 
during metastasis and can contribute to treatment 
resistance due to its antiapoptotic effects (Thiery et al., 
2009). Recently, KLF8 protein was found overexpressed 
in GC tissues and cell lines. In that study, shRNA was 
used to observe the silencing effect of KLF8 gene on in 
vitro and in vivo CG cell growth. The authors observed 
the inhibition of cell proliferation both in culture and in 
rats that were injected with GC cells (Liu et al., 2012). 
These results indicate that KLF8 gene silencing may be 
useful in GC treatment. 
 Versican protein, a component of the extracellular 
matrix found on tumor stroma and cancer cells, is encoded 
by the VCAN gene. Its activity is regulated by several 
cytokines, including IL-11, which performs an important 
role in the progression to GC. Versican overexpression 
promotes cell proliferation, differentiation and migration, 
thus contributing to the invasion and metastasis related 
to this neoplasia (Wight, 2002; Ricciardelli et al., 2009). 
Cultured GC cell lines and fourteen fresh frozen tissue 
samples from GC patients were treated with siRNA 
targeting the versican mRNA. The results revealed 
that low versican expression may create a hostile 
microenvironment for tumor progression by preventing 
subsequent stages of IL-11 mediated inflammation 
(Zhang et al., 2012). The study suggests a novel treatment 
possibility for GC by epigenetic avoidance of versican 
overexpression. 
 Researchers proudly obtained and demonstrated 
outstanding antitumor results, such as induction of 
sensitivity to drugs; inhibition of cell viability; reduction 
of tumor cell proliferation, invasion and progression; 
inflammation and migratory capacity blockage and finally, 
impairement of GC cell angiogenesis and metastasis. The 
studies that indicate the importance of RNAi in regulation 
and its antitumor effects in gastric carcinogenesis are 
briefly described in Table 1.
Table 1. Gene Knockdown Studies using RNA Interference Technology, and its Antitumor Effects in Gastric 
Carcinogenesis
Gene RNAi mechanism Antitumor effect Study type Reference
NANOG plasmid shRNA   Inhibition of cell proliferation, migration and invasion In vitro Ji and Jiang, 2013
STMN-1 shRNA Inhibition of proliferation and cell migration In vivo/In vitro Akhtar et al., 2013
CCDC134 synthetic siRNA Increase in invasion and migration In vitro Zhong et al., 2013
MUC1 synthetic siRNA  To increase sensitivity to trastuzumab In vitro Deng et al., 2013
BCL-2 synthetic siRNA Enhance the radiosensitivity and apoptosis In vitro Liu et al., 2013
RAB25 synthetic siRNA Inhibition of invasion and metastasis In vitro Cao et al., 2013
VEGF-A/C plasmid shRNA   Suppression of cancer growth In vitro Wang et al., 2013
AKT1 lentiviral shRNA To increase chemosensitivity to cisplatin  In vitro Zhou et al., 2012
APRIL lentiviral shRNA  Cell viability and colony formation inhibition  In vitro Cui et al., 2012
APRIL plasmid shRNA   Increase the apoptotic rate  In vitro Ni et al., 2012
CDX2 plasmid shRNA   Decreased proliferation, invasion and progression In vitro Wang et al., 2012
CLIC1 synthetic siRNA To suppress GC migration and invasion In vitro Peng-Fei et al., 2012
CTGF synthetic siRNA Hindered metastatic spreading and dissemination   In vitro Jiang et al., 2012
EPHA2 synthetic siRNA Inhibited proliferation and decreased tumor cell invasion In vitro Yuan et al., 2012
hMex-3A synthetic siRNA Inhibition of proliferation and migration capacity In vitro Jiang et al., 2012
IL-8 synthetic siRNA  Interruption of tumor cell migration and invasion In vitro Kuai et al., 2012
KLF8 lentiviral shRNA Inhibition of proliferation In vivo/In vitro Liu et al., 2012
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 Despite the amazing advances of RNAi biomolecular 
technology in causing significant antitumor effects, some 
of the investigators frustrations should be pointed out. 
Peng-Fei et al., (2012) prevented the in vitro migration 
and invasion of CG but unfortunately did not prevent 
the proliferation of these cancer cells. Similarly, Kuai 
et al., (2012) were able to contain CG migration and 
invasion, however, they induced a significant increase in 
chemoresistance related to oxaliplatin use.
 Several countries are currently initiating their studies, 
since most of the RNAi technological advances have 
been led by Asian researchers, especially in which 
concerns unraveling the relationship between genes and 
their functions in gastric carcinogenesis. This scientific 
revolution also occurs in various human cancers as the 
increased expression of certain genes is not unique to CG. 
Thus, controlling this expression by silencing appears as 
a hope for the development of new therapies for other 
cancers. Therefore, various medical and biological 
disciplines could investigate in developing countries this 
innovative RNAi technology.
 It is estimated that some of the innovative RNAi 
therapy properties could benefit clinical and industrial 
applications and consequently public health. These 
benefits would include:  improved toxicity profiles due 
to its specificity for the target, exclusively eliminating 
the expected protein; individualized treatment as RNAi 
would be rationally designed to block   any target gene 
expression; low production cost, due to its relative ease of 
synthesis compared to antibodies or recombinant growth 
factors.
 For these reasons, the RNAi mechanism is a promising 
class of medication effective against GC. On the other 
hand, some challenges may limit the overall effectiveness 
of this technology, such as the delivery system and the 
ideal RNAi release. This system should be formulated 
in order to be able to escape the endothelial reticulum in 
the tumor environment trajectory, thus preventing RNAi 
degradation and, consequently, treatment failure (Li and 
Huang, 2010).
 Important steps were taken to develop an efficient 
siRNA molecule delivery system in cells or target tissues 
for the successful application of RNAi. The lentiviruses 
belong to the family of retroviruses and can be used 
to deliver RNAi (now called shRNA). This shRNA is 
transfected and integrates into the cell genome, and after 
gaining stability in prolonged shRNA expression, it keeps 
the gene silenced (Naldini et al., 1996; Fish and Kruithof, 
2004), this being one of the exogenous genes delivery 
systems preferred by some of the researchers cited in 
this review (Cui et al., 2012; Liu et al., 2012; Zhou et 
al., 2012). Several strategies are theoretically proposed 
for targeting these molecules in order to ensure a better 
specificity in the target tissue, but tests are necessary which 
allow demonstrating efficacy in practice. 
Final Considerations
 Our review reveals how fast researchers are currently 
investigating new therapeutic possibilities for GC 
treatment with RNAi technology. In the last two years, 
substantial progress has been made in RNAi technology 
such as the interruption of important stages in gastric 
carcinogenesis related to the discovery of target oncogenes 
for future treatments in this area.
 Nowadays the main use of this technology is related to 
the investigation of new drugs and therapeutic targets in 
experimental trials. In the short term, we may probably be 
able to follow the steps to the development and validation 
of methodologies to determine the ability of these drugs 
in humans. It is estimated that in the future these clinical 
applications will be able to solve the reversal of multidrug 
resistance in the gastrointestinal oncology field, and the 
adverse effects of current chemotherapy such as toxicity 
and low survival rates, besides the high cost currently 
related to GC treatments.
 To contribute to the understanding of the RNAi 
technique, we attempted to synthesize the most recent 
available data and evaluate the research advances in GC 
treatment, which could be a solution to public health 
problems caused by this type of cancer.
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